Bio-Thera Solutions and Intract Pharma announced at the end of last month that they had entered into a global collaboration and licensing agreement that gives Bio-Thera access to two oral delivery technologies for monoclonal antibodies to develop treatments for chronic gastrointestinal inflammatory diseases.  According to Intract’s press release, “Intract has granted Bio-Thera a worldwide license to Intract’s oral biologics drug delivery platform for a single undisclosed mAb product.”  Intract also reported that under the deal, Intract will receive an undisclosed upfront payment, with potential development and commercial milestone payments along with royalties on product sales.  Bio-Thera will also have the option to expand development of the product for multiple GI indications and will be responsible for manufacturing and commercialization of any approved products.